Hosted on MSN1mon
Zoetis projects 6%-8% organic revenue growth for 2025 with strong companion animal performanceU.S. and international revenues grew at 11% and 10% operationally, respectively. The Simparica franchise grew 28% operationally, with Simparica Trio surpassing $1 billion in global revenue ...
Revenue growth in Q2 was driven by strong performance in its companion animal portfolio, which saw an 11% growth due to key products like Simparica Trio and Apoquel. Additionally, its new ...
NexGard: NexGard Products for Fleas, Ticks, and Heartworms in Dogs and Cats Simparica: Simparica Products for Fleas, Ticks, & Heartworms in Dogs ...
Stock fell by 9.83% in pre-market trading. Strong performance in the Simparica and dermatology franchises. 2025 revenue guidance set at $9.225-$9.375 billion. Zoetis demonstrated robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results